Literature DB >> 1381723

Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis.

C S Chu1, B C Trapnell, S M Curristin, G R Cutting, R G Crystal.   

Abstract

Cystic fibrosis (CF) is a recessive hereditary disorder, requiring both parental cystic fibrosis conductance transmembrane regulator (CFTR) genes to carry mutations for clinical disease to manifest, i.e., only 50% of normal CFTR gene expression is required to maintain a normal phenotype. To help define the minimum amount of normal CFTR gene expression necessary to maintain normalcy, we have capitalized on our prior observation (Chu, C.-S., B. C. Trapnell, J. J. Murtagh, Jr., J. Moss, W. Dalemans, S. Jallat, A. Mercenier, A. Pavirani, J.-P. Lecocq, G. R. Cutting, et al. 1991. EMBO [Eur. Mol. Biol. Organ] J. 10:1355-1363) that normal individuals can have up to 66% of bronchial CFTR mRNA transcripts that are missing exon 9, a region representing 21% of the sequence coding for the critical nucleotide (ATP)-binding fold 1 (NBF1) of the predicted CFTR protein. The study population included 78 individuals with no prior diagnosis of CF. Evaluation of bronchial epithelial cells (obtained by bronchoscopy) revealed that exon 9 was variably deleted in all individuals. Remarkably, there were four individuals, all greater than or equal to 35 yr, in whom bronchial epithelial cells exhibited 73, 89, 90, and 92% CFTR transcripts with inframe deletion of exon 9, respectively, despite normal sweat Cl- and no clinical manifestation of CF. In the context that only 8% or less of bronchial CFTR transcripts need exon 9 to maintain normal airway function, these observations strongly suggest that either exon 9 is not necessary for CFTR structure and/or function or that only a very small fraction of bronchial epithelial cells need to express normal CFTR mRNA transcripts with exon 9 to perform the function of CFTR sufficient to maintain a normal phenotype in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381723      PMCID: PMC329931          DOI: 10.1172/JCI115952

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Two patients with cystic fibrosis, nonsense mutations in each cystic fibrosis gene, and mild pulmonary disease.

Authors:  G R Cutting; L M Kasch; B J Rosenstein; L C Tsui; H H Kazazian; S E Antonarakis
Journal:  N Engl J Med       Date:  1990-12-13       Impact factor: 91.245

2.  Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport.

Authors:  S C Hyde; P Emsley; M J Hartshorn; M M Mimmack; U Gileadi; S R Pearce; M P Gallagher; D R Gill; R E Hubbard; C F Higgins
Journal:  Nature       Date:  1990-07-26       Impact factor: 49.962

3.  Small airways in idiopathic pulmonary fibrosis. Comparison of morphologic and physiologic observations.

Authors:  R G Crystal; J D Fulmer; W C Roberts; E R von Gal
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

4.  Altered regulation of airway epithelial cell chloride channels in cystic fibrosis.

Authors:  R A Frizzell; G Rechkemmer; R L Shoemaker
Journal:  Science       Date:  1986-08-01       Impact factor: 47.728

5.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

6.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

7.  Demonstration that CFTR is a chloride channel by alteration of its anion selectivity.

Authors:  M P Anderson; R J Gregory; S Thompson; D W Souza; S Paul; R C Mulligan; A E Smith; M J Welsh
Journal:  Science       Date:  1991-07-12       Impact factor: 47.728

8.  Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel.

Authors:  S H Cheng; D P Rich; J Marshall; R J Gregory; M J Welsh; A E Smith
Journal:  Cell       Date:  1991-09-06       Impact factor: 41.582

Review 9.  Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects.

Authors:  R G Crystal; J D Fulmer; W C Roberts; M L Moss; B R Line; H Y Reynolds
Journal:  Ann Intern Med       Date:  1976-12       Impact factor: 25.391

10.  Sweat chloride concentration in adults with pulmonary diseases.

Authors:  P B Davis; S Del Rio; J A Muntz; L Dieckman
Journal:  Am Rev Respir Dis       Date:  1983-07
View more
  31 in total

Review 1.  Gene transfer for cystic fibrosis.

Authors:  M J Welsh
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.

Authors:  P W Miller; A Hamosh; M Macek; P A Greenberger; J MacLean; S M Walden; R G Slavin; G R Cutting
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 3.  Genetics and pulmonary medicine. 1. The genetics of cystic fibrosis lung disease.

Authors:  D J Davidson; D J Porteous
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

4.  A rare frameshift variant in trans with the IVS9-5T allele of CFTR in a Chinese pedigree with congenital aplasia of vas deferens.

Authors:  Bin Ge; Mingzhe Zhang; Ruyi Wang; Dejing Wang; Tengyan Li; Hongjun Li; Binbin Wang
Journal:  J Assist Reprod Genet       Date:  2019-11-10       Impact factor: 3.412

5.  Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.

Authors:  B G Harvey; P L Leopold; N R Hackett; T M Grasso; P M Williams; A L Tucker; R J Kaner; B Ferris; I Gonda; T D Sweeney; R Ramalingam; I Kovesdi; S Shak; R G Crystal
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 6.  Impact of gene editing on the study of cystic fibrosis.

Authors:  Patrick T Harrison; David J Sanz; Jennifer A Hollywood
Journal:  Hum Genet       Date:  2016-06-21       Impact factor: 4.132

Review 7.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

8.  Highly Efficient Gene Editing of Cystic Fibrosis Patient-Derived Airway Basal Cells Results in Functional CFTR Correction.

Authors:  Shingo Suzuki; Ana M Crane; Varada Anirudhan; Cristina Barillà; Nadine Matthias; Scott H Randell; Andras Rab; Eric J Sorscher; Jenny L Kerschner; Shiyi Yin; Ann Harris; Matthew Mendel; Kenneth Kim; Lei Zhang; Anthony Conway; Brian R Davis
Journal:  Mol Ther       Date:  2020-04-29       Impact factor: 11.454

Review 9.  Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling.

Authors:  D A S de Souza; F R Faucz; L Pereira-Ferrari; V S Sotomaior; S Raskin
Journal:  Andrology       Date:  2017-12-07       Impact factor: 3.842

10.  Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.

Authors:  Nicholas E King; Shingo Suzuki; Cristina Barillà; Finn J Hawkins; Scott H Randell; Susan D Reynolds; Barry R Stripp; Brian R Davis
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.